Butler Hospital

Nemours Children's Health Names Delaware Valley Regional President

Retrieved on: 
Monday, October 30, 2023
Harvard Business School, Woman, Strategic planning, Nemours, Region, JD, Bar, Care New England, Albany Medical College, New York University Stern School of Business, Research, Johns Hopkins Children's Center, Boston Children's Hospital, Mumford, Nemours Children's Hospital, Delaware, Quality, Union University, Hospital, Butler Hospital, Nursing, Management, Delaware Valley, New York University

WILMINGTON, Del., Oct. 30, 2023 /PRNewswire/ -- Nemours Children's Health announced today that Mark Marcantano, JD, will join the organization as Regional President for Nemours Children's Delaware Valley.

Key Points: 
  • WILMINGTON, Del., Oct. 30, 2023 /PRNewswire/ -- Nemours Children's Health announced today that Mark Marcantano, JD, will join the organization as Regional President for Nemours Children's Delaware Valley.
  • He will report to Mark Mumford, Nemours Enterprise Chief Operating Officer (COO) for the multistate, multisite children's health system.
  • "Mark brings a perfect blend of both ambulatory and inpatient experience to the new role of Regional President for Nemours Children's Health, Delaware Valley," said Mumford.
  • "There is no more inspiring focus than the mission and vision at Nemours Children's Health to provide the highest quality, value-based pediatric healthcare necessary to create the healthiest generations of children," said Marcantano.

Rhode Island experts come together to discuss a new era of Alzheimer's disease treatment and research

Retrieved on: 
Wednesday, September 6, 2023
Molecular biology, Medicaid, Cell biology, National Advisory Council (India), University, Ray Hall, Biochemistry, Prostate cancer, Forgetting, Rhode Island Department of Health, Research, Bangladesh Technical Education Board, Ageing, Portrait, Memory, Organization, Center for Global Infectious Disease Research, Brown University, Butler Hospital, Psychiatry, Alpert Medical School, AD, FDA, Caregiver, Breast cancer, Disease, Pharmaceutical industry, Alzheimer's disease, Neuroscience

Maritza Ciliberto , member of the National Institutes of Health's National Advisory Council on Aging, AD care partner/research advocate and participant.

Key Points: 
  • Maritza Ciliberto , member of the National Institutes of Health's National Advisory Council on Aging, AD care partner/research advocate and participant.
  • Gregorio Valdez , Ph.D, GLF Translational Associate Professor of molecular biology, cell biology and biochemistry at Brown University.
  • In Rhode Island, some 24,000 people aged 65 and older are living with the disease, and 36,000 caregivers provide 51 million hours of unpaid care.
  • Organizations including Butler Hospital, the Rhode Island Department of Health and the Rhode Island Alzheimer's Association will be on-hand to share information, answer questions and connect attendees with relevant resources.

iRxReminder receives National Institute of Health Grant for AI Telehealth research to improve Tardive Dyskinesia Outcomes

Retrieved on: 
Thursday, April 6, 2023
Depression, UT, Psychology, TD, Schizophrenia, SBIR, OH, Health, Princeton University Department of Economics, Butler Hospital, Intelligence, Research, CMO, Consultant, Kent State University, Patient, Child, Brown University, Movement disorder, Rare, Provo, Tardive dyskinesia, NIH, Bipolar disorder, Wellness, Pharmaceutical industry, Nursing

iRxReminder's research partners; -- Provo, UT based Videra Health, New York City based Fermata Health, and Cleveland, OH based Charak Health and Wellness--will join in to validate the use of artificial intelligence with telehealth for early disorder detection, allowing for more timely clinical intervention. iRxReminder's patented technology is expected to also help TD patients adhere to their antipsychotic medication regimens by providing reminders and tracking tools, which further helps avoid costly adverse events or unexpected crisis activities, thus driving improved patient outcomes with reduced care costs.

Key Points: 
  • Company will collaborate with Videra Health, Kent State University, Brown University and Butler Hospital, Fermata Health, and Charak Center for Health and Wellness to validate the effectiveness of their Tardive Dyskinesia detection and remote monitoring platform.
  • There is no cure for TD, treatment costs are significant, and can exceed $50,000 per patient, annually.
  • "We are honored to receive this grant from the NIH and excited about the potential of our platform to improve the lives of patients with Tardive Dyskinesia," said Anthony Sterns, Ph.D., CEO of iRxReminder.
  • iRxReminder's grant is part of the program's efforts to support research into the treatment of rare diseases.

Boston IVF Adds Award-Winning Reproductive Endocrinologist Dr. Gary Frishman to Rhode Island and Massachusetts Fertility Center Teams

Retrieved on: 
Thursday, June 16, 2022
Fertility, Gynaecology, SRS, Journal, University of Pennsylvania, IUI, Graduate medical education, Obstetrics, University, IVF, Columbia University, RI, Society, AAGL, Accreditation, Brown University, News, Genetic testing, Education, McGovern Medical School, American Association, Infertility, Women's health, Alpert Medical School, Reproductive medicine, Clinical, Patient, Butler Hospital, Association, Royal Australian and New Zealand College of Obstetricians and Gynaecologists, MBA, Environment, Research, ART, Family, National Medical Commission, Accreditation Council, Birth control, Medicine, MD, Woman

WALTHAM, Mass., June 16, 2022 /PRNewswire-PRWeb/ -- Boston IVF, a worldwide leader in reproductive healthcare, research, and education, is pleased to announce the addition of award-winning and internationally recognized reproductive endocrinologist Gary Frishman, MD to its growing fertility treatment practice.

Key Points: 
  • WALTHAM, Mass., June 16, 2022 /PRNewswire-PRWeb/ -- Boston IVF , a worldwide leader in reproductive healthcare, research, and education, is pleased to announce the addition of award-winning and internationally recognized reproductive endocrinologist Gary Frishman, MD to its growing fertility treatment practice.
  • A mainstay in the Providence reproductive medicine community since 1991, Dr. Frishman has been selected as a Top Fertility Doctor by Rhode Island Monthly Magazine in every issue since its inception.
  • Double board-certified in reproductive endocrinology and infertility, Dr. Frishman joins Boston IVF from Women and Infants Hospital in Providence, RI.
  • "To add a reproductive endocrinologist of Dr. Frishman's vast experience to the Boston IVF physician team is substantial and truly great news for our patients," said David Stern, MBA CEO of Boston IVF.

Butler Raises Additional $32M to Continue Building the Hospitality Platform of the Future

Retrieved on: 
Thursday, October 28, 2021
Room service, Technology, City, Travel, Industry, Forbes, Shamrock Holdings, CEO, Multimedia, Butler, Butler Hospital, Solution, F&B, Hotel

The company's platform of products and solutions are designed to foster community and connect travelers with the cities around them.

Key Points: 
  • The company's platform of products and solutions are designed to foster community and connect travelers with the cities around them.
  • With this investment, Butler will more than double their presence to 12 markets across the US, with plans to service nearly 250,000 rooms.
  • "From the start we've had this vision of building a platform that will improve the travel experience for all.
  • While Butler creates the most powerful and efficient hospitality network, they continue to build new products and solutions for the industry.

LifeBio Secures Second National Institute on Aging Grant; Research Will Use Artificial Intelligence as a Possible Diagnostic Tool for Alzheimer's

Retrieved on: 
Tuesday, October 12, 2021
Trial of the century, Eye, Dementia, Method, National, Government, National Institute, Associate, Time, RT, HIV disease progression rates, Loneliness, Research, Brown University, Health, Hospital, Quality of life, Psychiatry, Neurodegeneration, Butler Hospital, Small Business Innovation Research, CEO, Alzheimer's Association, SBIR, Communication, Association, Biomarker, Partnership, Intelligence, Disease, Clinical trial, Organization, NIA, Pharmaceutical industry, Medical imaging, Medicine

"Reminiscence therapy has been an effective tool in dementia care and in addressing social determinants of health.

Key Points: 
  • "Reminiscence therapy has been an effective tool in dementia care and in addressing social determinants of health.
  • Our current LifeBio Memory solution as well as this new tool, LifeBioALZ, will use artificial intelligence to take person-centered care and contextualized health to a new level."
  • This document references projects supported by the National Institute on Aging of the National Institutes of Health under Federal Award Identification Number R43AG076341 (LifeBio-ALZ) and R44AG069566 (LifeBio Memory).
  • LifeBio is also the creator of MyHello, a tech-powered, automated phone visit platform to connect participants live for weekly conversations using proven methods.

Neurolief Announces First Patient Enrolled in Clinical Study Evaluating Its Brain Neuromodulation System in Treating Major Depressive Disorder

Retrieved on: 
Thursday, September 23, 2021
Mental Health, Medical Devices, Health, Other Health, Clinical Trials, Pharmaceutical, Linda, Hamilton Rating Scale for Depression, ADHD, Sleep, Chronic pain, Review, Depression, Hope, Alpert Medical School, Brown University, Therapy, Randomized controlled trial, FDA, Multimedia, Patient, Behavior, Physician, Pediatric Attention Disorders Diagnostic Screener, Sadness, MD, Metabolic pathway, Insomnia, MDD, Butler Hospital, Head, Lists of diseases, Mental health, Death, Grammatical mood, Pain, Hamilton, Trial of the century, Migraine, Technology, National Institute, Psychiatry, Appetite, Work, Safety, Anxiety, Industry, Neuroscience, Pharmaceutical industry, Medical device

Neurolief Ltd ., a neurotechnology innovator, today announced enrollment of the first patient in its pivotal clinical study evaluating Relivion DP for the treatment of major depressive disorder (MDD).

Key Points: 
  • Neurolief Ltd ., a neurotechnology innovator, today announced enrollment of the first patient in its pivotal clinical study evaluating Relivion DP for the treatment of major depressive disorder (MDD).
  • The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders.
  • The first patient was enrolled at Butler Hospital, Brown Department of Psychiatry and Human Behavior, Providence, RI.
  • The MOOD trial is designed as a prospective, multi-center, two-arm, double-blind, randomized controlled trial, followed by an open-label active treatment phase.